The FDA could be just months away from approving Eli Lilly and Boehringer Ingelheim's drug candidate to treat a common condition.
Eli Lilly (NYSE: LLY) is a top healthcare company, and it has generated mild but consistent growth over the years. Has Eli Lilly's stock climbed too quickly and gotten too expensive, or is this still a stock that could go higher? In December, several analysts updated their price targets for Eli Lilly.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.